
Please try another search
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Rolf Karl-Heinz Hoffmann | 62 | 2018 | Independent Non-Executive Director |
Hans Peter Hasler | 68 | 2018 | Independent Non Executive Chairman |
Michael Stockham | - | - | Notable Scientific Advisory Board |
Geoffrey A. Block | 58 | - | Notable Scientific Advisory Board |
Maria Fabiana Lacerca-Allen | 57 | 2021 | Independent Non-Executive Director |
Jonathon Powell | - | - | Notable Scientific Advisory Board |
Christoph Gasche | - | - | Notable Scientific Advisory Board |
Rudolf Stefan Widmann | - | 2024 | Non-Executive Director |
Anders Lundstrom | 63 | 2021 | CEO & Executive Director |
Christian Schweiger | 59 | 2008 | Co-Founder & Non Executive Director |
Peter Llewellyn-Davies | 67 | 2016 | Independent Vice Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review